ERNA logo

ERNA Ernexa Therapeutics Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$1.69
+0.01 (+0.60%)

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cyt…

Market Cap: $2.86Mwww.ernexatx.com

Price

No data yet.

Social Signal Score

28
5d
—
30d
—
60d
23
3 mentions
—
90d
33
6 mentions
—
news: 6

Revenue

$0.00
$0.00$162.3K$324.7K$487.0K
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-4050.00
$-4050.00–$-4050.00
1 analysts
FY2026
$-18.02
$-18.02–$-18.02
1 analysts
FY2027
$-1.86
$-1.86–$-1.86
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Sanjeev Luther
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
2.74
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-58.55
www.ernexatx.com